Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults [PDF]
Vaccines, 2022 Mumps outbreaks and breakthrough infections of measles and rubella have raised concerns about waning of vaccine-induced immunity after two doses of measles-mumps-rubella (MMR) vaccination.
Patricia Kaaijk +1 more
exaly +4 more sources
Measles-Mumps-Rubella Vaccine and COVID-19 Relationship. [PDF]
mBio, 2020 I have read the article by Fidel and Noverr with great interest (1). As told in the article, could measles-mumps-rubella (MMR) vaccine really be a “low-risk–high-reward” measure in COVID-19? However, I have several concerns about their opinion/hypothesis posed in their article (1).
Özdemir Ö.
europepmc +3 more sources
Comparative long-term follow-up study of persistence of immunity after JVC-001 measles, mumps, and rubella vaccination in Japanese children [PDF]
Human Vaccines & ImmunotherapeuticsJVC-001 is a novel measles-mumps-rubella (MMR) combined vaccine. In the J301 clinical trial, healthy 1-y-old Japanese children received either JVC-001 or marketed measles-rubella (MR) and mumps vaccines as control group.
Tetsuo Nakayama +5 more
doaj +2 more sources
Comparative analysis of immunogenicity of Chinese MMR and MR vaccines following primary vaccination in infants in Gansu Province [PDF]
Scientific ReportsTo systematically compare the immunogenicity differences between measles-mumps-rubella combined (MMR) vaccine and measles-rubella combined (MR) vaccine following first dose vaccination in 8–9-month-old infants, with emphasis on evaluating the response ...
Xue-feng Liang +3 more
doaj +2 more sources
Determination of ELISA reactive mumps IgG antibodies in MMR vaccine recipients in comparison with MMR vaccine naive children: A cross sectional study [PDF]
Scripta Medica, 2021 Background/Aim: Mumps is by vaccine preventable infectious disease characterised by parotitis. In India mumps vaccines are not currently used under National Immunisation Programme (NIP).
Gupta Riya, Saxena Naveen, Gupta Parul
doaj +1 more source
Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose [PDF]
Open Forum Infectious Diseases, 2020 Patricia Kaaijk
exaly +2 more sources
Эпидемиология и вакцинопрофилактика, 2021 Relevanc. Measles, mumps and rubella, despite many years of vaccination, retain their epidemiological and social significance at the present time. The aim of the work is to study the safety and immunogenicity. Of the vaccine for the prevention of measles,
I. V. Feldblium +9 more
doaj +1 more source
Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age [PDF]
Vaccine, 2020 Inna G Ovsyannikova +2 more
exaly +2 more sources
Quality analysis of a combined domestic vaccine for the prevention of measles, rubella and mumps
Вопросы вирусологии, 2022 Introduction. The need to maintain a high level of vaccination coverage against measles, rubella and mumps in conditions of an increased risk of outbreaks of infections due to violations of vaccination tactics associated with the pandemic of coronavirus ...
Anna S. Binyatova +5 more
doaj +1 more source
A Review on Rubella Vaccine: Iran (1975-2019) [PDF]
Archives of Razi Institute, 2021 The first Attenuated rubella vaccine was developed by Parkman and Meyer in 1966. Ten years later in the 1975s, the rubella vaccine was developed in Razi Vaccine and serum research institute) RVSRI).
A Shafayi, A Mohammadi
doaj +1 more source